Synthesis and Characterization of Compounds Potentially Related to the Janus Kinase Inhibitor Baricitinib

被引：2
|
作者：
Dasari, S. R. [1 ,2 ]
Seelam, N. [1 ]
Jayachandra, S. [2 ]
Vadali, L. R. [2 ]
Yerva, E. R. [2 ]
Tondepu, S. [3 ]
Gadakar, M. K. [2 ]
机构：
[1] Koneru Lakshmaiah Educ Fdn, Dept Chem, Guntur, Andhra Pradesh, India
[2] Mylan Labs Ltd, Hyderabad, Telangana, India
[3] Vignans Fdn Sci Technol & Res, Dept Chem Engn, Guntur, Andhra Pradesh, India
来源：
RUSSIAN JOURNAL OF ORGANIC CHEMISTRY | 2019年 / 55卷 / 10期
关键词：
Baricitinib; rheumatoid arthritis; synthesis; characterization; Baricitinib-related substances; INDOLES;
D O I：
10.1134/S1070428019100166
中图分类号：
O62 [有机化学];
学科分类号：
070303 ; 081704 ;
摘要：
Nine compounds potentially related to the Janus kinase inhibitor Baricitinib have been identified, synthesized by conventional methods, and characterized by IR, H-1 and C-13 NMR, and mass spectral data.
引用
收藏
页码：1569 / 1574
页数：6
相关论文
共 50 条
  • [31] Dehydrocrenatidine Is a Novel Janus Kinase Inhibitor
    Zhang, Jing
    Zhu, Ning
    Du, Yuping
    Bai, Qifeng
    Chen, Xing
    Nan, Jing
    Qin, Xiaodong
    Zhang, Xinxin
    Hou, Jianwen
    Wang, Qin
    Yang, Jinbo
    MOLECULAR PHARMACOLOGY, 2015, 87 (04) : 572 - 581
  • [32] Filgotinib (Jyseleca®), a Janus kinase inhibitor
    Buxeraud, Jacques
    Faure, Sebastien
    ACTUALITES PHARMACEUTIQUES, 2022, 61 (616): : 10 - 11
  • [33] Primary Myelofibrosis-Related Renal Disorders Treated with a Janus Kinase Inhibitor
    Asou, Mea
    Asakawa, Tomohiko
    Araki, Makoto
    Ehara, Takashi
    Hishima, Tsunekazu
    Sakamaki, Hisashi
    CASE REPORTS IN NEPHROLOGY AND DIALYSIS, 2021, 11 (01): : 1 - 9
  • [34] ADDITIONAL COSTS RELATED TO ORAL JANUS KINASE INHIBITOR USE IN ATOPIC DERMATITIS
    Robinson, Stephen
    Kallala, Rami
    Jo-Hansen, Christian Dall
    Panek, Malgorzata
    Nikodem, Mateusz
    Chudzik, Kamila
    Damentko, Magdalena
    Brandi, Henrik
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 33 - 34
  • [35] Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection
    Akbarzadeh-Khiavi, Mostafa
    Torabi, Mitra
    Rahbarnia, Leila
    Safary, Azam
    INFECTION, 2022, 50 (02) : 295 - 308
  • [36] Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection
    Mostafa Akbarzadeh-Khiavi
    Mitra Torabi
    Leila Rahbarnia
    Azam Safary
    Infection, 2022, 50 : 295 - 308
  • [37] Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials
    Sumit Kunwar
    Christopher E. Collins
    Florina Constantinescu
    Clinical Rheumatology, 2018, 37 : 2611 - 2620
  • [38] Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials
    Kunwar, Sumit
    Collins, Christopher E.
    Constantinescu, Florina
    CLINICAL RHEUMATOLOGY, 2018, 37 (10) : 2611 - 2620
  • [39] Preliminary Response to Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis
    Kim, Hanna
    Dill, Samantha
    O'Brien, Michelle
    Jain, Minal
    Lu, Shajia
    Tsai, Wanxia
    Shi, Yinghui
    Vian, Laura
    Gadina, Massimo
    Millwood, Michelle
    Brundidge, April
    Rider, Lisa G.
    Colbert, Robert
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [40] Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis
    Verstovsek, Srdan
    POSTGRADUATE MEDICINE, 2013, 125 (01) : 128 - 135
12345